By Nigam Arora & Dr. Natasha Arora
Signal(s) to enter, add, reduce, exit, hold or change.
News
Boston Scientific (BSX) stock is jumping 6.25% to $53.92 as of this writing on a positive surprise from ADVENT study. Farapulse Pulsed Field Ablation is a system in which electric fields selectively ablate heart tissue in patients with atrial fibrillation. The study shows that the system is not inferior to radiofrequency or cryoablation that are now standard-of-care.
Approval
In The Arora Report Analysis, the system is likely to be approved by next year.
Model Portfolio
BSX is in the core Model Portfolio.
Aging Population
The population is aging. Afib is more common in older patients. The prevalence of other heart diseases is also more common in older patients. Boston Scientific also makes pacemakers and defibrillators. The company also makes stents.
Boston Scientific is a beneficiary of the aging population.
Zones
For those who are following the Good Way, the Buy Now rating is 🔒 (To see the locked content, please take a 30 day free trial).
For those following the Best Way, the buy zone is 🔒.
To learn about the Good Way and the Best Way, read the Getting a Running Start Guide.
The recommended quantity is 30% – 50%.
The very long term target remains $102 – $110.
What To Do Now
Those in the stock may consider continuing to hold. Those not in the stock may consider following the parameters given above.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
